Biomea Fusion(US:BMEA) Globenewswire·2026-03-14 08:30Core Viewpoint - Biomea Fusion, Inc. announced positive 52-week follow-up results from its Phase II COVALENT-111 study on icovamenib for type 2 diabetes, indicating durable efficacy and safety [1][2]. Study Design and Results - COVALENT-111 was a double-blind, randomized, placebo-controlled trial involving 267 adult patients with type 2 diabetes, focusing on those with inadequate glycemic control despite treatment [3][4]. - The study evaluated three dosing regimens of icovamenib, with a total of 163 patients completing at least 80% of their planned dosing prior to a clinical hold [4]. - Positive results were observed across multiple subgroups, with significant reductions in HbA1c levels, particularly in severe insulin-deficient diabetes patients, achieving a reduction of 1.2% at Week 52 [5][6]. Safety Profile - Icovamenib maintained a favorable safety profile throughout the 52-week observation period, with no treatment-related serious adverse events reported [7]. Future Developments - The company plans to initiate two new Phase II studies targeting patients who showed the best responses in the COVALENT-111 trial [2]. - Initial clinical weight-reduction data from the Phase I GLP-131 study for obesity is anticipated in the second quarter of 2026 [9]. About Icovamenib - Icovamenib is an investigational small molecule targeting menin, which is implicated in beta-cell dysfunction, potentially transforming diabetes treatment by addressing underlying biological mechanisms [10][11]. Market Context - Diabetes affects over 38 million Americans, representing a significant economic burden on the U.S. healthcare system, with severe insulin-deficient diabetes being a high unmet medical need [12]. Company Overview - Biomea Fusion is focused on developing oral small molecule therapies for diabetes and obesity, aiming to deliver transformative treatments for metabolic disorders [13].